Market Place
Sourcing Support
Myrtelle Reports NAA Reduction In Canavan Disease Gene Therapy
10 Oct 2024 //
BUSINESSWIRE
Myrtelle Reports NAA Reduction in Canavan Disease Gene Therapy Trial
01 Oct 2024 //
PR NEWSWIRE
Moderna and Myrtelle among those picked for FDA rare disease programme
06 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Myrtelle: FDA Selects rAAV-Olig001-ASPA For Canavan START Program
05 Jun 2024 //
PR NEWSWIRE
Myrtelle Announces Presentation of Data in Study of rAAV-Olig001-ASPA
10 Oct 2023 //
BUSINESSWIRE
Myrtelle to Present Positive Post-Treatment Data in Study of rAAV-Olig001-ASPA
31 May 2023 //
BUSINESSWIRE
Myrtelle Announces Positive Data in Phase 1/2 Trial of rAAV-Olig001-ASPA
09 Jan 2023 //
BUSINESSWIRE
Myrtelle and Forge Biologics Form Manufacturing Partnership
07 Oct 2022 //
CONTRACTPHARMA
CNS-focused gene therapy biotech forges manufacturing deal for hearing loss drug
06 Oct 2022 //
ENDPTS
Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2
04 Oct 2022 //
BUSINESSWIRE
Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA Cgmpmfg
03 Oct 2022 //
BUSINESSWIRE
Myrtelle concludes preliminary stage of Canavan disease gene therapy trial
12 Jan 2022 //
CLINICALTRIALSARENA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.